ClinicalTrials.gg
CompletedNCT03787017Updated Dec 27, 2018

A Study to Compare MP-513 20mg & Metformin XR 1000mg FDC With Coadministration of the Two Separate Drugs

A Phase 1 interventional study of FDC(MP-513 20mg/Metformin XR 1000mg) and MP-513 20mg in Healthy Volunteers, sponsored by Handok Inc.. Completed at 1 site in Korea, Republic of. Open to male participants aged 20 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2018-12-27.

Sponsored by Handok Inc. · Phase 1, Interventional, and Other

From the registry’s dates

  • Registered 1 year 9 months after the study started (first participant enrolled Jan 2014, registered Oct 2015).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
36
Allocation
Randomized
Ages
20 Years to 45 Years
Sex
Male
01

Study summary

The purpose of this study is to compare the safety and pharmacokinetic characteristics of fixed-dose combination of MP-513 20mg and Metformin XR 1000mg with coadministration of the two separate drugs in healthy male volunteers.

Read the detailed description
  1. Randomized, Open-label, Single-dosing, Two-treatment, Two-sequence, Two-period, crossover design
  2. Wash-out period : 14days from the first dosing
  3. Drug concentration analytical device : UPLC-MS/MS
02

Conditions studied

  • Healthy Volunteers
03

In context

Lead sponsor

Handok Inc. is the lead sponsor of 46 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years to 45 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • A healthy male adult at the age of 20 to 45 (both inclusive) at the time of screening test.
  • Body weight equal to or greater than 55 kg and calculated ideal body weight (IBW) within ±20%
  • An individual who has been given and fully understood detailed explanations about this study, decides to participate in the study of his own will, and provides written to comply with instructions.

Exclusion criteria

Exclusion Criteria:

  • History or presence of any diseases in the hepatobiliary, renal, nervous(central or peripheral), respiratory, hemato-oncology, cardiovascular, urinary, musculoskeletal, immune, ear, nose and throat (ENT), mental, and, particularly, endocrine systems (e.g., diabetes mellitus, hyperlipidemia, etc.).
  • History of any gastrointestinal disease that may affect absorption of the study drug (Crohn's disease, ulcer, acute or chronic pancreatitis, etc.) or gastrointestinal surgeries (except for simple appendectomy or hernia repair).
  • to MP-513 or drugs containing metformin or other drugs in the same class as ingredients or to other drugs
  • Vital signs in a sitting position corresponding to at least one of the following criteria: systolic blood pressure ≥ 140 mmHg or \< 90 mmHg, or diastolic blood pressure ≥ 95 mmHg or \< 60mmHg.
  • Serum creatine > upper limit of reference range
  • Required to refrain from food intake for at least 24 hours during the study period due to surgery or religious reason.
  • History or presence of drug abuse.
  • Administration of drugs that either induce or inhibit drug metabolizing enzymes, such as barbitals, within 1 month prior to the first dosing.
  • Intake of food or beverage containing grapefruit or cranberry within 1 week prior to the first dosing.
  • Administration of any ethical drugs or traditional Korean herbal medicines within 2 weeks or any over-the-counter drugs or vitamin products within 1 week prior to the first dosing
  • An individual who participated in another clinical trial and was administered any product within 2 months prior to the first dosing.
  • Whole blood donation within 2 months, apheresis donation within 1 month, or blood transfusion within 1 month prior to the first dosing.
  • An individual who drinks excessive amounts of alcohol (more than 21 units/week, 1 unit =10 g of pure alcohol) or who cannot stop drinking alcohol from 24 hours prior to hospital admission through to hospital discharge.
  • Having smoked 10 cigarettes/day or more on average over the past 3 months.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
36 participants (actual)

Study arms

  • Experimental
    Sequence Group A

    1. 1st period : coadministration of 1 tablet of MP-513 20mg and 1 tablet of Metformin XR 1000mg, single-dose under fasted 2. 2nd period : 1 tablet of FDC(MP-513 20mg/Metformin XR 1000mg), single-dose under fasted

    Drug: FDC(MP-513 20mg/Metformin XR 1000mg) · Drug: MP-513 20mg · Drug: Metformin XR 1000mg

  • Experimental
    Sequence Group B

    1. 1st period : 1 tablet of FDC(MP-513 20mg/Metformin XR 1000mg), single-dose under fasted 2. 2nd period : coadministration of 1 tablet of MP-513 20mg and 1 tablet of Metformin XR 1000mg, single-dose under fasted

    Drug: FDC(MP-513 20mg/Metformin XR 1000mg) · Drug: MP-513 20mg · Drug: Metformin XR 1000mg

Interventions

06

What researchers measure

Primary outcomes

  1. AUC of MP-513 and metformin

    PK assessment

    Time frame: - 0(pre-dose), 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 10, 12, 24, 36, 48, 72 hours post-dose(a total of 36 times, with 18 times per period)

  2. Cmax of MP-513 and metformin

    PK assessment

    Time frame: - 0(pre-dose), 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 10, 12, 24, 36, 48, 72 hours post-dose(a total of 36 times, with 18 times per period)

07

Study locations

1 site
  • Clinical trials center of Chungnam National University Hospital
    Daejeon, Jung-gu 301-721, Korea, Republic of
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2014 to primary completion in Aug 2014, 7 months.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 5, 2015
First posted
Dec 26, 2018
StartActual
Jan 2014
Primary completionActual
Aug 2014
CompletionActual
Sep 2014
Last update
Dec 27, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 27, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03787017
Lead sponsor
Handok Inc.
Responsible party
Sponsor
First posted
Dec 26, 2018
Start date
Jan 2014
Primary completion
Aug 2014
Completion
Sep 2014
Last update
Dec 27, 2018
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Teneligliptin · Metformin

Start the discussion